Altmetrics
Downloads
262
Views
126
Comments
0
This version is not peer-reviewed
Submitted:
18 July 2024
Posted:
19 July 2024
You are already at the latest version
First Author (year) | Study type (method) |
Study population(s) (controls and patients) |
Clinical presentation | Surgical outcome | ||
Non-black | black | Non-black | black | |||
Goodney [10] (2013) | Retrospective cohort study Intervention: Thoracic aneurysm repair Control: Mortality Data source: Medicare claims (1999-2007) |
N=722 black patients N= 14,583 non-black patients (97% White, 1.0% Native American, 0.9% Hispanic, 0.9% Asian American, 0.1% Pacific Islander, 0.1 % missing) |
Older presentation (74.5 vs 73,7; P=0 .001) 4,4% ruptured TAA. (7.3% vs 4.4%; P=0.001) Non-black patients had a higher ratio of men (56,4% vs. 43,4%; p=0,02) |
Younger presentation (74.5 vs 73.7; P= 0.001) 7,3% ruptured TAA (7.3% vs 4.4%; P=0.001) Black patients had a higher Charlson comorbidity score (1,51 vs 0,92; p=0,001) Black patients had a higher prevalence of diabetes, heart failure, renal failure and history of malignancy (p=0.001) |
Open surgical repair: lower perioperative mortality 6.8% non-black; P < 0.001. 5-year survival: 61% P < 0.001. |
Open surgical repair: higher perioperative mortality 14.4% black; P < 0.001. Operative mortality: OR 2.0; 95% CI 1.5-2.5; P < 0.0001. 5-year survival: 71%; P < 0.001. |
Yin [11] (2021) | Retrospective cohort study Intervention: Thoracic endovascular aneurysm repair Control: 30-day mortality Data source: VQI national data registry |
N= 684 black patients N= 2021 non-black patients (100% white) |
1488 aneurysms (73,6%) | More likely to undergo emergent TEVAR (27.6% vs. 19.8%; P < 0.001). More likely symptomatic (52.3% vs. 36.4%; P < 0.001). More likely to receive blood transfusion (32.1% vs. 23.6%; P < 0.001). |
30-Day Mortality: No significant difference in 30 day mortality: (3.4% vs 4.9%; P =0.1) |
30-Day Mortality: Following correction for operative variables, comorbidities, and demographics: black race was independently associated with 56% decrease in risk after Tevar (OR 0.44; 95% CI 0.22-0.85; P = 0.01). Postoperative Complications: No independent association (OR 0.90; 95% CI 0.68-1.17; P = 0.42). 1-year overall survival: log-rank P= 0.024 1-year mortality Hr:0.65; 95% CI, 0.47-0.91; P=0.01 |
Diaz-Castrillon [12] (2022) | Retrospective cohort study Intervention: Thoracic endovascular aneurysm repair Control: In-hospital mortality Data source: Nationwide inpatient sample (NIS) 2010-2017 |
N= 4,959 black N=20,301 non-black (68,1% white, 5,7% Hispanic, 6,5% others) |
CAD more prevalent (34.6% (white) vs. 24.1% (black) vs. 26.8% (Hispanic) vs. 24.7% (others); p < .001). COPD more prevalent (28.7% vs. 15.6% vs. 15.1% vs. 16.5%; p < .001). TEVAR often times elective (58.8% vs. 34% vs. 48.3% vs. 48.2%; p < .001). |
Hypertension more frequent as a comorbidity (92% (black) vs. 83%(white) vs. 85% (Hispanic) vs. 84% (others); p < .001) |
Racial disparities do not appear to be associated with in-hospital mortality. | Racial disparities do not appear to be associated with in-hospital mortality. |
Tanious [13] (2019) | Retrospective cohort study Intervention: Thoracic endovascular aneurysm repair Control: In-hospital mortality Data source: Florida State Agency for Health Care Administration 2000-2014 |
N= 1,630 black N= 34,119 non-black (47.7% White, 46.0% Hispanic,1.8%) other.) |
Older presentation 67,42 (black) vs. 73.87 (white) vs. 73,52 (Hispanic) vs. 72,06 (other); P< 0.001 |
Higher prevalence of women 31,5% (black) vs. 16,1 (white) vs. 20,2 (Hispanic) vs. 21,8 (other); P< 0.001 |
Chance of in-hospital mortality: 2,5% (white), 2,8% (Hispanic), 5,1% (other); p<0,0001 |
Chance of in-hospital mortality: 4,0%; P<0,0001 |
Johnston [14] (2013) | Retrospective cohort study Intervention: Thoracic endovascular aneurysm repair Control: TEVAR performance based on race Data source: Nationwide inpatient sample (NIS) 2005-2008 |
N= 4,108 black N = 41,122 non-black (86% white, 6,2% Hispanic, 3,2% Asian or Pacific Islander, 0,8% Native American, 3,7% other) |
NA | 28.6% of black patients received TEVAR, whereas only 19.5% of white patients were treated with TEVAR (P < .001) |
TEVAR performance: Odds ratio: Native American: 2.37 Black: 1.71 Hispanic: 1.70 Asian or Pacific Islander: 1.34 Other: 0.98 White (reference): 1 |
Tevar performance: Odds: Black: 1.71 |
Murphy [15] (2013) | Retrospective cohort study Intervention: Thoracic endovascular aneurysm repair Control: mortality Data source: Nationwide inpatient sample (NIS) 2001-2005 |
N=819 black N= 9,738 non-black (88% white, 5,7% Hispanic, 6,8 other) |
High prevalence for elective surgery: 48%; P < 0,001 |
High prevalence for emergency surgery: 20%; P < 0,001 |
Mortality rate: 9,8%; P < 0,001 |
Mortality rate: 13,7%; P < 0,001 |
Abdulameer [16] (2019) |
Retrospective cohort study Intervention: Thoracic aneurysm rupture Control: Mortality per million Data source: U.S. National Vital Statistics System 1999-2016 |
N=104,458 total ruptures |
NA | NA | Mortality/ million White women: 3,5 White men: 3,3 Asian men: 1,5 Asian women: 2,5 (P<0,001) |
Mortality/ million Black women: 2.3 Black men: 2,6 (P<0,001) |
Vervoort [17] (2021) | Retrospective cohort study Intervention: Elective thoracic endovascular aneurysm repair Control: Reintervention and surgical outcome Data source: Vascular Quality Initiative 2009-2018 |
N= 2,140 black N= 40,431 Non-black (100% white) |
Women sex 33,8% (23), p=0.02 Aortic neck in mm 28,2+/-15,8 p=0,01 CHF: 6,0 (4) p=0,01 Smoking history: 89,7 (61) p < 0,01 |
Women sex 19,3% (212), p=0.02 Aortic neck in mm 23,8+/-5,25 p=0,01 CHF: 13,0 (143) p=0,01 Smoking history: 83,1 (911) p < 0,01 |
All-cause mortality: similar between groups (log-rank P = 0.25) Reintervention: White race statistically associated with reintervention; P = 0.01 |
All-cause mortality: similar between groups (log-rank P = 0.25) Reintervention: hr: 0,7; p=0,01 |
Ribieras [18] (2023) | Retrospective cohort study Intervention: thoracic endovascular aneurysm repair Control: All-couse mortality Data source: Global Registry for Endovascular Aortic Treatment (GREAT) 2010-2016 |
N= 79 black N=359 non-black |
Chronic obstructive pulmonary disease: Black 6.3% vs White 20.1%; P = 0.003 Cardiac arrhythmia: Black 10.1% vs White 20.6%; P = 0.037 |
Younger presentation: 62 years vs 67 years); P < 0.001. Higher BMI 31.0 kg/m2 vs 27.5 kg/m2); P < 0.001. Renal insufficiency: 35.4% vs 17.8%; P = 0.001. Higher incidence of erectile dysfunction in black patients 6.3% vs 2.0%; P = 0.047. Higher incidence of hypertension: common in black patients (100% vs 86.5%; P = 0.034). Higher prevalence of diabetes mellitus: 18.8% vs 4.5%; P = 0.021. |
All-cause mortality: no significant difference | Complications: 34.3% vs 17.4%; P = 0.014 Conversion to open repair: 2.9% vs 0%; P = 0.011 Type II endoleaks: 5.7% vs 1.0%; P = 0.040 All-cause mortality: no significant difference |
Murphy [19] (2010) | Retrospective cohort study Intervention: Thoracic aneurysm rupture Control: Mortality Data source: U.S. National Vital Statistics System 2001-2005 |
N=104 black N= 699 non-black (93% white, 7% Hispanic) |
Men: 450/650 (white), 32/49 (Hispanic); P < 0,001 |
Men: 54/104 P < 0,001 |
Overall mortality: 13.3% (n=117), no differences between patients of varied ethnicity Mortality: 12% (white), 10% (hispanic), 19% (other); p=303 |
Overall mortality: 13.3% (n=117), no differences between patients of varied ethnicity Mortality:12% died; p=0,303 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 MDPI (Basel, Switzerland) unless otherwise stated